Enterococcus faecalis is a Gram-positive, facultative anaerobic bacterium that is a normal inhabitant of the human intestine. It is a member of the Enterococcus genus, which includes several species of bacteria that are commonly found in the environment and in the human body. Enterococcus faecalis is known to cause a wide range of infections, including urinary tract infections, endocarditis, and bacteremia. Despite its clinical significance, there is still much to be learned about this microbe. This article will explore the current understanding of Enterococcus faecalis, including its structure, physiology, genetics, and virulence factors.
Enterococcus faecalis is a small, Gram-positive, spherical bacterium. It is approximately 1.5-2 µm in diameter and is non-motile. The cell wall of Enterococcus faecalis is composed of a thick peptidoglycan layer, which is surrounded by a thin layer of lipoteichoic acid. The cell wall is responsible for the bacterium’s resistance to a variety of antibiotics, including penicillin and vancomycin.
Enterococcus faecalis is a facultative anaerobe, which means it can grow in both aerobic and anaerobic environments. It is able to utilize a variety of carbon sources, including glucose, fructose, sucrose, and glycerol. It is also capable of utilizing a variety of nitrogen sources, including ammonia, nitrate, and nitrite. Enterococcus faecalis is able to survive in a wide range of temperatures, pH levels, and salt concentrations.
Enterococcus faecalis is a genetically diverse species, which can be divided into several distinct clades. These clades are differentiated by their genetic makeup, which can be used to determine the virulence potential of a particular strain. Enterococcus faecalis is capable of producing a variety of virulence factors, including enterococcal surface protein (Esp), cytolysin, and gelatinase. These virulence factors are responsible for the bacterium’s ability to cause a wide range of infections.
Enterococcus faecalis is a major cause of nosocomial infections, which are infections acquired in a healthcare setting. The most common infections caused by Enterococcus faecalis are urinary tract infections, bacteremia, and endocarditis. These infections are often difficult to treat due to the bacterium’s resistance to many antibiotics. Enterococcus faecalis is also known to cause opportunistic infections in immunocompromised individuals.
Enterococcus faecalis is a Gram-positive, facultative anaerobic bacterium that is a normal inhabitant of the human intestine. It is a major cause of nosocomial infections, including urinary tract infections, bacteremia, and endocarditis. Despite its clinical significance, there is still much to be learned about this microbe. This article has explored the current understanding of Enterococcus faecalis, including its structure, physiology, genetics, and virulence factors.
1.
Reduced Suicide Rates in Cancer Patients; Enhanced Circadian Rhythm; HIV Vaccine for Cancer Patients?
2.
DNA's hidden shape reveals target to reverse ovarian cancer chemoresistance
3.
For patients with prostate cancer, long-term follow-up helps identify treatment side effects.
4.
Can patients receiving immunotherapy for cancer benefit from taking vitamin D supplements?
5.
Chemotherapy can be a challenging treatment?here's how to deal with some of the side-effects
1.
Blastic Plasmacytoid Dendritic Cell Neoplasm and the Dawn of AI-powered Diagnostics
2.
Unlocking the Secrets of Squamous Cell Carcinoma: New Hope for Patients
3.
Precision Cancer Risk Mitigation Strategies
4.
Unlocking the Mysteries of Lymphoblastic Lymphoma: A Journey Into the Unknown
5.
Exploring the Use of Bevacizumab in Treating Different Types of Cancers
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
2.
Efficient Management of First line ALK-rearranged NSCLC - Part II
3.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
4.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
5.
Innovations in Hematology
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation